CareCost Prior authorization
Criteria-based
coverage criteria reviewed before payment
Check what the payer requires before you schedule Lupron Depot.
Prior authorization · duration limits · clinical prerequisites · dosing
20 of 30 payer policy sets hold a leuprolide acetate policy · source-linked · reviewed August 2026
Aetna + endometriosis is shown as a live example until you choose a payer.
Aetna applies coverage criteria to leuprolide acetate before it pays rather than naming a separate PA step, so the same documentation must be ready before treatment.
Covered under ICD-10 N80.
Endometriosis - for initial treatment of endometriosis
What opens in CareCost
Aetna · Lupron Depot · Endometriosis
For every requirement: the exact payer criteria, the source citation, a check-off, and a save to the patient’s chart.
In CareCost: check off each requirement · save to the patient · print for the chart
Aetna · Lupron Depot · Endometriosis
You have already checked the policy, indication and covered dose. Open the remaining requirements and work them as a patient checklist.
CareCost tracks Lupron Depot coverage requirements across 20 payer policy sets.
Aetna · Anthem / Elevance · Cigna · UnitedHealthcare · Centene · Premera · BCBS plans + more
Coverage clearance is only the first step.
CareCost carries the same patient through the entire workflow.
Finish this patient’s estimate →17 of 20 commercial payers with a leuprolide acetate policy require prior authorization. Clinical prerequisites, duration limits and dosing rules vary by indication and by plan. Ten payers CareCost tracks (including Kaiser Permanente WA, Regence and Wellmark) carry no leuprolide acetate policy at all.
17 of 20 require PA · 5 of 20 require another product first · 2 restrict site of care · 7 rules address reauthorization
Many commercial payers require approval before leuprolide acetate is purchased or administered.
Coverage depends on the diagnosis in the payer’s leuprolide acetate policy: endometriosis or uterine fibroids with anemia before surgery, each carrying its own duration limit.
Plans may require a documented trial of a contraceptive, an NSAID or depot medroxyprogesterone for endometriosis, or a failed month of iron alone for fibroids, before paying for leuprolide acetate.
Every commercial quantity limit in this corpus is written as a course length, not a milligram ceiling: commonly 3 to 6 months depending on the indication, sometimes with one renewal.
The billed kit must match the diagnosis-specific policy criteria: 3.75 mg (1 unit) monthly or 11.25 mg (3 units) every 3 months. A claim billed at the prostate-cancer strengths is a different product (J9217), not Lupron Depot.
A plan can also limit where the injection is given, requiring an office setting rather than allowing self-administration.
Some payers cap the initial approval and require a new documented request to continue past it, most often for endometriosis; a fibroid course usually may not be renewed at all.
Retreatment of endometriosis is labeled only in combination with norethindrone acetate 5 mg daily. Several payer reauthorization criteria name this add-back requirement directly rather than leaving it as a clinical recommendation only.
Lupron Depot has no biosimilar carrying a CMS payment limit under J1950, so payer policies do not set a preferred-product step the way they do for some other 96372 drugs. What every one of these policies sets instead is a duration: a maximum course length, written in months or in kits, that governs how long the payer will keep paying regardless of the diagnosis.
| Payer | Indication | Duration limit | Renewal |
|---|---|---|---|
| Aetna Commercial |
Endometriosis / Fibroids | “lifetime maximum of 12 months total” (endometriosis retreatment) / “lifetime maximum of 6 months total” (fibroids) | Retreatment is covered inside the same lifetime cap |
| Anthem / Elevance Commercial |
Endometriosis | “3.75 mg, 7.5 mg 1 kit per 4 weeks” | “Retreatment: A single course may be approved for 6 months. Total duration of therapy should not exceed 12 months” |
| Florida Blue Commercial |
Endometriosis / Fibroids | “dosage does not exceed 3.75 mg every 4 weeks (28 days) or 11.25 mg every 12 weeks (84 days)” | Not stated in the policy language CareCost has read |
| BCBS Minnesota Commercial |
Endometriosis / Fibroids | “3 billable units every 84 days” for both indications | Endometriosis “may be renewed up to one time only for 6 months”; fibroids “may NOT be renewed” |
| Premera Commercial |
Endometriosis | “Initial approval will be for 90-days. Note: Coverage for Lupron Depot 4-month and 6-month formulations will be prohibited” | Not stated in the policy language CareCost has read |
| UnitedHealthcare Commercial |
Endometriosis / Fibroids | “Initial treatment course is limited to a maximum of 6 months” (endometriosis) / “no more than 3 months” (fibroids) | “Duration of both the initial and recurrent course of therapies is no longer than 12 months total” |
No prior authorization for Part B leuprolide acetate. Coverage follows the diagnosis codes in the Medicare policy: the governing local coverage determinations are published in the CMS Medicare Coverage Database, and a MAC can differ from its neighbour on the same drug.
This is the Original Medicare answer. A Medicare Advantage plan still administers the same Part B benefit, though it may add its own prior-authorization and preferred-product requirements on top; confirm that plan’s specific policy rather than assuming the Original Medicare rules below carry over.
Coverage of injectable GnRH agonists is set by whichever local coverage determination your MAC publishes, and a MAC can differ from its neighbor on covered diagnosis codes and documentation. Check your specific MAC’s published LCD rather than assume any single set of requirements applies nationally. Search the CMS Medicare Coverage Database →
These prerequisite trials are not set by a Medicare LCD; they are common in commercial policy. UnitedHealthcare requires “Contraindication, intolerance, or failure of initial treatment with both of the following: Oral contraceptives or depot medroxyprogesterone… and Non-steroidal anti-inflammatory drugs (NSAIDs)” for endometriosis. Cigna will approve after “A contraceptive (e.g., combination oral contraceptives, levonorgestrel-releasing intrauterine systems …), OR” a similar trial. BCBS South Carolina requires a “trial of at least 6 months, or history of intolerance or contraindication to” danazol or a combination oral contraceptive.
Payer citation language above is drawn from CareCost’s own leuprolide acetate policy corpus (20 payers). Check the specific payer’s language →
It depends on the payer and plan. 17 of the 20 commercial leuprolide acetate policies CareCost has read require prior authorization before Lupron Depot is covered; most of the rest require a documented trial of another product first. Check this patient’s payer →
Endometriosis is a covered indication under all 20 leuprolide acetate policies CareCost has read, and uterine fibroids with anemia before surgery under 18 of them: each with its own duration limit and clinical prerequisites. Check coverage →
Every commercial quantity limit in the corpus is written as a course length, not a milligram ceiling: commonly 6 months for an initial endometriosis course and 3 months for a fibroid course, with a single renewal available for endometriosis at most payers. Check duration limits →
Start with the specific prerequisite the Lupron Depot diagnosis calls for: a documented contraceptive or NSAID trial for endometriosis, a failed month of iron alone for fibroids, the planned surgery date, or, for endometriosis retreatment, the norethindrone acetate add-back the label requires. CareCost turns the applicable payer policy into a patient-level checklist showing each requirement, what to confirm, and the source language supporting it. Open patient clearance →
Data current: payer policies Aug 2026 · reviewed dates come from each payer
CareCost draws each requirement from the payer's own medical and specialty-drug policy documents: prior-authorization criteria, preferred-product rules and clinical coverage criteria, with Medicare coverage read from the CMS Medicare Coverage Database. Every requirement links back to its source policy.